Optimizing the early phase development of new analgesics by human pain biomarkers.
about
Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related DisordersHeat pain detection threshold is associated with the area of secondary hyperalgesia following brief thermal sensitization: a study of healthy male volunteersCan quantitative sensory testing predict responses to analgesic treatment?Translational pain biomarkers in the early development of new neurotherapeutics for pain management.Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.
P2860
Optimizing the early phase development of new analgesics by human pain biomarkers.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Optimizing the early phase development of new analgesics by human pain biomarkers.
@en
Optimizing the early phase development of new analgesics by human pain biomarkers.
@nl
type
label
Optimizing the early phase development of new analgesics by human pain biomarkers.
@en
Optimizing the early phase development of new analgesics by human pain biomarkers.
@nl
prefLabel
Optimizing the early phase development of new analgesics by human pain biomarkers.
@en
Optimizing the early phase development of new analgesics by human pain biomarkers.
@nl
P2860
P356
P1476
Optimizing the early phase development of new analgesics by human pain biomarkers.
@en
P2093
Hans Christian Hoeck
P2860
P304
P356
10.1586/ERN.11.147
P577
2011-11-01T00:00:00Z